- Home
- OTLY vs TSHA Comparison
OTLY vs TSHA Comparison
Compare OTLY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- TSHA
- Stock Information
- Founded
- OTLY 1994
- TSHA 2019
- Country
- OTLY Sweden
- TSHA United States
- Employees
- OTLY N/A
- TSHA N/A
- Industry
- OTLY Packaged Foods
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- TSHA Health Care
- Exchange
- OTLY Nasdaq
- TSHA Nasdaq
- Market Cap
- OTLY 256.5M
- TSHA 262.4M
- IPO Year
- OTLY 2021
- TSHA 2020
- Fundamental
- Price
- OTLY $9.27
- TSHA $1.76
- Analyst Decision
- OTLY Buy
- TSHA Strong Buy
- Analyst Count
- OTLY 4
- TSHA 8
- Target Price
- OTLY $19.75
- TSHA $6.63
- AVG Volume (30 Days)
- OTLY 108.9K
- TSHA 2.7M
- Earning Date
- OTLY 04-30-2025
- TSHA 05-13-2025
- Dividend Yield
- OTLY N/A
- TSHA N/A
- EPS Growth
- OTLY N/A
- TSHA N/A
- EPS
- OTLY N/A
- TSHA N/A
- Revenue
- OTLY $823,666,000.00
- TSHA $8,333,000.00
- Revenue This Year
- OTLY $3.92
- TSHA N/A
- Revenue Next Year
- OTLY $6.14
- TSHA N/A
- P/E Ratio
- OTLY N/A
- TSHA N/A
- Revenue Growth
- OTLY 5.15
- TSHA N/A
- 52 Week Low
- OTLY $6.00
- TSHA $1.05
- 52 Week High
- OTLY $26.80
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- OTLY 50.76
- TSHA 61.26
- Support Level
- OTLY $8.40
- TSHA $1.13
- Resistance Level
- OTLY $8.90
- TSHA $1.98
- Average True Range (ATR)
- OTLY 0.43
- TSHA 0.16
- MACD
- OTLY 0.04
- TSHA 0.08
- Stochastic Oscillator
- OTLY 76.79
- TSHA 76.34
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.